TY - JOUR
T1 - Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures
T2 - A meta-analysis
AU - Misra, Deepika
AU - Leibowtiz, Keith
AU - Gowda, Ramesh M.
AU - Shapiro, Michael
AU - Khan, Ijaz A.
PY - 2004/11
Y1 - 2004/11
N2 - Background: Contrast-induced nephropathy is one of the common causes of acute renal insufficiency after cardiovascular procedures. Hypothesis: The objective of this paper was to analyze the published data on the usefulness of N-acetylcysteine in the prevention of contrast-induced nephropathy after these procedures. Methods: Trials were selected if they were prospective, randomized, controlled, had selected patients with impaired renal function, used low-osmolality, nonionic contrast media intra-arterially, administered a total of four doses of N-acetylcysteine in addition to intravenous saline hydration, and had contrast-induced nephropathy as their primary outcome. Contrast-induced nephropathy was defined as an increase in serum creatinine concentration by >0.5 mg/dl or a 25% increase above baseline at or within 48 h post procedure. Meta-analysis was performed using the Fisher's Combined Test with a measure of effect size. The magnitude of the N-acetylcysteine effect was estimated using random-effects models. Homogeneity was evaluated using the chi-square test of homogeneity and standard Q statistic. Reporting bias was explored by the Rosenthal method. Results: The Fisher's Combined Test was significant at p<0.005 in favor of N-acetylcysteine, The size of the N-acetylcysteine effect was to reduce contrast-induced nephropathy by 20%. There was a 62% relative risk reduction in contrast-induced nephropathy with N-acetylcysteine using a fixed-effects model, and a 70% relative risk reduction using the random-effects model, in addition, we found that 27 unpublished trials showing no effects of N-acetylcysteine would exist to overturn the combined significance of p<0.005 of the five trials in our meta-analysis. Conclusion: Oral administration of N-acetylcysteine in addition to intravenous saline hydration has a beneficial effect in the prevention of contrast-induced nephropathy after cardiovascular procedures in patients with impaired renal function.
AB - Background: Contrast-induced nephropathy is one of the common causes of acute renal insufficiency after cardiovascular procedures. Hypothesis: The objective of this paper was to analyze the published data on the usefulness of N-acetylcysteine in the prevention of contrast-induced nephropathy after these procedures. Methods: Trials were selected if they were prospective, randomized, controlled, had selected patients with impaired renal function, used low-osmolality, nonionic contrast media intra-arterially, administered a total of four doses of N-acetylcysteine in addition to intravenous saline hydration, and had contrast-induced nephropathy as their primary outcome. Contrast-induced nephropathy was defined as an increase in serum creatinine concentration by >0.5 mg/dl or a 25% increase above baseline at or within 48 h post procedure. Meta-analysis was performed using the Fisher's Combined Test with a measure of effect size. The magnitude of the N-acetylcysteine effect was estimated using random-effects models. Homogeneity was evaluated using the chi-square test of homogeneity and standard Q statistic. Reporting bias was explored by the Rosenthal method. Results: The Fisher's Combined Test was significant at p<0.005 in favor of N-acetylcysteine, The size of the N-acetylcysteine effect was to reduce contrast-induced nephropathy by 20%. There was a 62% relative risk reduction in contrast-induced nephropathy with N-acetylcysteine using a fixed-effects model, and a 70% relative risk reduction using the random-effects model, in addition, we found that 27 unpublished trials showing no effects of N-acetylcysteine would exist to overturn the combined significance of p<0.005 of the five trials in our meta-analysis. Conclusion: Oral administration of N-acetylcysteine in addition to intravenous saline hydration has a beneficial effect in the prevention of contrast-induced nephropathy after cardiovascular procedures in patients with impaired renal function.
KW - Cardiac catheterization
KW - Contrast induced nephropathy
KW - Coronary angiography
KW - N-acetylcysteine
KW - Percutanous coronary intervention
KW - Radio contrast dyes
KW - Renal failure
UR - http://www.scopus.com/inward/record.url?scp=7444227936&partnerID=8YFLogxK
U2 - 10.1002/clc.4960271106
DO - 10.1002/clc.4960271106
M3 - Article
C2 - 15562929
AN - SCOPUS:7444227936
VL - 27
SP - 607
EP - 610
JO - Clinical Cardiology
JF - Clinical Cardiology
SN - 0160-9289
IS - 11
ER -